Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Invested Capital (2016 - 2025)

Historic Invested Capital for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $608.4 million.

  • Arrowhead Pharmaceuticals' Invested Capital rose 95445.75% to $608.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $608.4 million, marking a year-over-year increase of 95445.75%. This contributed to the annual value of $543.4 million for FY2025, which is 18441.72% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Invested Capital stood at $608.4 million, which was up 95445.75% from $543.4 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Invested Capital peaked at $749.2 million during Q1 2025, and registered a low of $57.7 million during Q4 2024.
  • For the 5-year period, Arrowhead Pharmaceuticals' Invested Capital averaged around $413.0 million, with its median value being $427.6 million (2021).
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 6678.45% in 2024, then skyrocketed by 95445.75% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Invested Capital (Quarter) stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then plummeted by 56.17% to $173.7 million in 2023, then tumbled by 66.78% to $57.7 million in 2024, then soared by 954.46% to $608.4 million in 2025.
  • Its Invested Capital was $608.4 million in Q4 2025, compared to $543.4 million in Q3 2025 and $562.3 million in Q2 2025.